I struggle to see the negative. Is a completely different product to SRX. I agree that if anything, is a positive from the perspective of possible competition. OF course, the SRX announcement was somewhat ambiguous and uninformative in terms of data so more info is required, but scientifically, there is no rationale to affect OSL prospects.
- Forums
- ASX - By Stock
- Impact of Sirflox failure to meet primary end point
OSL
oncosil medical ltd
Add to My Watchlist
5.69%
!
$1.16

I struggle to see the negative. Is a completely different...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.16 |
Change
-0.070(5.69%) |
Mkt cap ! $16.49M |
Open | High | Low | Value | Volume |
$1.25 | $1.25 | $1.11 | $72.36K | 60.96K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9286 | $1.16 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.18 | 412 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9286 | 1.160 |
1 | 7500 | 1.080 |
2 | 19761 | 1.050 |
1 | 2500 | 1.030 |
1 | 550 | 1.020 |
Price($) | Vol. | No. |
---|---|---|
1.180 | 412 | 1 |
1.200 | 8677 | 1 |
1.245 | 2418 | 1 |
1.250 | 46027 | 1 |
1.300 | 1500 | 1 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
OSL (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online